Department of Neurology, Chang Gung Memorial Hospital, Keelung, 204, Taiwan.
Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, 204, Taiwan.
Transl Psychiatry. 2024 Aug 16;14(1):333. doi: 10.1038/s41398-024-03049-w.
Older adults with major depressive disorder (MDD) or early cognitive decline during the subjective cognitive decline (SCD) stage may exhibit neuropsychiatric symptoms such as anxiety, depression, and subtle cognitive impairment. The clinicopathological features and biological mechanisms of MDD differ from those of SCD among older adults; these conditions thus require different treatment strategies. This study enrolled 82 participants above 50 years old with normal cognitive levels from the communities to examine biomarker-behavior correlations between MDD (n = 23) and SCD (n = 23) relative to a normal control (NC) group (n = 36). Multidomain assessments were performed for all participants, including immunomagnetic reduction tests to detect plasma beta-amyloid (Aβ), total tau (Tau), phosphorylated tau-181 (p-Tau181), neurofilament light chain, and glial fibrillary acidic protein (GFAP). This study observed that depressive symptoms in MDD were associated with amyloid pathology (plasma Aβ40 vs. HADS-D: R = 0.45, p = 0.031; Aβ42/Aβ40 vs. HADS-D: R = -0.47, p = 0.024), which was not observed in the NC (group difference p < 0.05). Moreover, cognitive decline in MDD was distinguished by a mixed neurodegenerative process involving amyloid (plasma Aβ42 vs. facial memory test: R = 0.48, p = 0.025), tau (Tau/Aβ42 vs. digit symbol substitution test (DSST): R = -0.53, p = 0.01), and astrocytic injury (plasma GFAP vs. Montreal cognitive assessment score: R = -0.44, p = 0.038; plasma GFAP vs. DSST: R = -0.52, p = 0.014), findings that did not apply to the NC (group difference p < 0.05). Moreover, this study revealed different biomarker-behavior correlations between individuals with SCD and the NC. Compared with the NC, cognitive decline in the SCD group might be unrelated to amyloid pathology and instead might be early manifestations of tau pathology. This study underscores the difference in clinicopathological features between MDD and SCD among older adults, which differ from those of the NC. These findings enhance our understanding of the mechanisms underlying MDD and SCD in older individuals.
患有重度抑郁症(MDD)或在主观认知衰退(SCD)阶段早期认知能力下降的老年人可能会出现焦虑、抑郁和轻微认知障碍等神经精神症状。老年人的 MDD 和 SCD 的临床病理特征和生物学机制不同;因此,这些病症需要不同的治疗策略。本研究招募了 82 名来自社区的 50 岁以上认知正常的参与者,以检查 MDD(n=23)和 SCD(n=23)与正常对照组(n=36)之间的生物标志物-行为相关性。对所有参与者进行了多领域评估,包括免疫磁减少测试以检测血浆β-淀粉样蛋白(Aβ)、总 tau(Tau)、磷酸化 tau-181(p-Tau181)、神经丝轻链和神经胶质纤维酸性蛋白(GFAP)。本研究观察到 MDD 中的抑郁症状与淀粉样蛋白病理学有关(血浆 Aβ40 与 HADS-D:R=0.45,p=0.031;Aβ42/Aβ40 与 HADS-D:R=-0.47,p=0.024),但在 NC 中没有观察到(组间差异 p<0.05)。此外,MDD 中的认知能力下降通过涉及淀粉样蛋白的混合神经退行性过程来区分(血浆 Aβ42 与面部记忆测试:R=0.48,p=0.025)、tau(Tau/Aβ42 与数字符号替代测试(DSST):R=-0.53,p=0.01)和星形胶质细胞损伤(血浆 GFAP 与蒙特利尔认知评估分数:R=-0.44,p=0.038;血浆 GFAP 与 DSST:R=-0.52,p=0.014),这些发现不适用于 NC(组间差异 p<0.05)。此外,本研究揭示了 SCD 个体与 NC 之间不同的生物标志物-行为相关性。与 NC 相比,SCD 组的认知能力下降可能与淀粉样蛋白病理学无关,而可能是 tau 病理学的早期表现。本研究强调了老年人 MDD 和 SCD 之间临床病理特征的差异,与 NC 不同。这些发现增强了我们对老年人 MDD 和 SCD 机制的理解。